Lumacaftor for Heart Failure

(LYRIC-HF Trial)

This trial explores whether Lumacaftor can improve brain function and blood flow in individuals with heart failure. Heart failure with reduced ejection fraction often causes cognitive issues, and no treatments currently target this problem specifically. Participants will receive either Lumacaftor or a placebo to determine if Lumacaftor makes a difference. Ideal candidates have experienced stable heart failure for some time and have not been hospitalized for it in the past three months. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of people.

Research has shown that lumacaftor is generally safe. One study found it was well-tolerated by healthy volunteers, with no serious side effects. Another study demonstrated that the combination of lumacaftor and ivacaftor was mostly safe for children aged 2 to 5 years. While lumacaftor is approved for conditions like cystic fibrosis, it can cause side effects, including eye and liver issues, so specific monitoring is recommended. Overall, lumacaftor has maintained a good safety record in various situations.¹²³⁴⁵

Unlike the standard treatments for heart failure, which often include beta-blockers, ACE inhibitors, and diuretics, Lumacaftor is unique because it targets the underlying cellular mechanisms of heart cells. Researchers are excited about Lumacaftor because it has the potential to directly influence protein folding and trafficking, which could improve heart function at a cellular level. This new mechanism of action offers a different approach compared to traditional treatments that primarily manage symptoms rather than address cellular dysfunctions. If successful, Lumacaftor could represent a significant advancement in heart failure therapy by providing a more targeted treatment option.

This trial will compare Lumacaftor with a placebo to evaluate its effects on heart failure. Studies have shown that Lumacaftor can improve lung function in people with cystic fibrosis by enhancing the CFTR protein's function, potentially normalizing cell activity. Research also indicates that Lumacaftor improves blood flow in the brain in heart failure models, which is crucial for cognitive functions like thinking and memory. These findings suggest that Lumacaftor might address cognitive issues in heart failure patients by enhancing brain blood flow.⁴⁶⁷⁸⁹